A PHASE 3, INTERNATIONAL, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED CLINICAL TRIAL TO STUDY THE EFFICACY, IMMUNOGENICITY, AND SAFETY OF THE 9VHPV VACCINE, A MULTIVALENT L1 VIRUS-LIKE PARTICLE VACCINE, IN THE PREVENTION OF ORAL PERSISTENT INFECTION WITH HPV TYPES 16, 18, 31, 33, 45, 52, OR 58 IN ADULT MALES, 20 TO 45 YEARS OF AGE.

Merck Sharp & Dohme Corp., una subsidiaria de Merck & Co. Inc.,0 个研究点目标入组 0 人开始时间: 2020年2月13日最近更新: 2024年8月20日

适应症

试验速览

阶段: 未知
状态: 招募中
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

入选标准

•1. Is healthy and is judged to be in good physical health based on medical history and physical examination.
•2. Is male, from 20 years to 45 years of age inclusive, at the time of signing the informed consent.
•3. Provides written informed consent for the study. The participant may also provide consent for future biomedical research. However, the participant may participate in the main study without participating in future biomedical research.
•4. Agrees to provide study personnel with a primary telephone number as well as an alternate means of contact, if available (such as an alternate telephone number or e- mail) for follow-up purposes.
•5. Can read, understand, and complete the eVRC.
•6.Has had at least 1 lifetime sexual partner.
•Please refer to the protocol for more information.

排除标准

•1. Has a history of HPV-related anal lesion (anal intraepithelial neoplasia or anal cancer) or HPV-related head and neck cancer.
•2. Has a history of or clinical evidence at the Day 1 external genital examination of HPV-related external lesion (condyloma acuminata, penile intraepithelial neoplasia or penile cancer).
•3. Has clinical evidence at the Day 1 external genital examination of gross genital lesion suggesting sexually transmitted disease.
•4. Has a fever (defined as oral temperature ≥100.0°F or ≥37.8°C) within the 24-hour period prior to the Day 1 visit.
•5. Has a history of severe allergic reaction (eg, swelling of the mouth and throat, difficulty breathing, hypotension, or shock) that required medical intervention.
•6. Is allergic to any vaccine component, including aluminum, yeast, or BENZONASETM (nuclease, Nycomed [used to remove residual nucleic acids from this and other vaccines]). For this exclusion criterion, an allergy to vaccine components is defined as an allergic reaction that met the criteria for severe AEs or SAEs defined in Appendix 3.
•7. Has known thrombocytopenia or any coagulation disorder that would contraindicate intramuscular injections.
•8. Is currently immunocompromised or has been diagnosed as having congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition.
•9. Has a history of splenectomy.
•10. Has a history or current evidence of any condition, therapy, lab abnormality or other circumstance that might confound the results of the study, or interfere with the participant’s participation for the full duration of the study, such that it is not in the best interest of the participant to participate by judgement of investigator.
•11. Is, at the time of signing informed consent, a user of recreational or illicit drugs or has had a recent history (within the last year) of drug or alcohol abuse or dependence at the discretion of the investigator. Alcohol abusers are defined as those who drink despite recurrent social, interpersonal, and/or legal problems because of alcohol use.
•12. Has received within 12 months prior to enrollment, is receiving, or plans to receive during Day 1 through Month 7 of the study, the following immunosuppressive therapies: radiation therapy, cyclophosphamide, azathioprine, methotrexate, any chemotherapy, cyclosporin, leflunomide (AravaTM), TNF-α antagonists, monoclonal antibody therapies (including rituximab [Rituxan™]), IVIG, antilymphocyte sera, or other therapy known to interfere with the immune response. Regarding systemic corticosteroids, a participant will be excluded if he is currently receiving steroid therapy, has recently (defined as within 2 weeks of Day 1 vaccination) received such therapy, or has received 2 or more courses of high-dose corticosteroids (≥20 mg/day of prednisone [or equivalent] orally or parenterally) lasting at least 1 week in duration in the year prior to Day 1 vaccination. Participants using inhaled, nasal, or topical steroids are considered eligible for the study.
•13. Has received within the 3 months prior to the Day 1 vaccination, is receiving, or plans to receive during Day 1 through Month 7 of the study, any immune globulin product (including RhoGAM™ [Ortho-Clinical Diagnostics]) or blood-derived product other than I

研究者

发起方

Merck Sharp & Dohme Corp., una subsidiaria de Merck & Co. Inc.,

相似试验

进行中（未招募）

1 期

Trial to evaluate the analgesic efficacy and safety of ibuprofen arginine/tramadol compared with ibuprofen alone and placebo, in patients with moderate to severe pain after non-oncological abdominal hysterectomy.Evaluation of the analgesic efficacy in patients with moderate to severe pain after non-oncological abdominal surgery.MedDRA version: 17.1Level: PTClassification code 10021151Term: HysterectomySystem Organ Class: 10042613 - Surgical and medical procedures

EUCTR2014-004081-21-ESaboratorios Farmalíder S.A.444

进行中（未招募）

不适用

EUCTR2014-004081-21-HUaboratorios Farmalíder S.A.444

进行中（未招募）

1 期

A Study to Evaluate the Efficacy and Safety of Obinutuzumab Versus Mycophenolate Mofetil (MMF) in Patients with Childhood Onset Idiopathic Nephrotic SyndromeChildhood Onset Idiopathic Nephrotic SyndromeMedDRA version: 21.1Level: PTClassification code 10029164Term: Nephrotic syndromeSystem Organ Class: 10038359 - Renal and urinary disorders

EUCTR2022-000369-42-BEF. Hoffman-La Roche Ltd.80

招募中

3 期

A phase III trial of RO5072759 in childhood onset idiopathic nephrotic syndrome patientsChildhood Nephrotic Syndrome

JPRN-jRCT2011220036Will Pendergraft, M.D., Ph.D.80

进行中（未招募）

1 期

EUCTR2022-000369-42-PLF. Hoffman-La Roche Ltd80